Mekonos is building a next-generation microfluidic chip platform for engineering cell therapies. One of the major challenges in producing cell therapies is proper delivery of molecules, such as vectors, into the cells. By combining synthetic biology with microfluidics, Mekonos is using their proprietary silicon-based cell-engineering platform to create a novel delivery approach. Their approach, Iris, is a System-on-a-Chip delivery platform that enables targeted delivery, multiplexing and dose control with digital precision. Iris delivers nucleic acids, protein complexes and small molecules into cells, enabling Mekonos to partner with many companies and teams to test and further develop their cell and gene therapy products. For example, Mekonos has partnered with Neochromosome to advance cell engineering for personalized medicines.

<p>Mekonos is building a next-generation microfluidic chip platform for engineering cell therapies. One of the major challenges in producing cell therapies is proper delivery of molecules, such as vectors, into the cells. By combining synthetic biology with microfluidics, Mekonos is using their proprietary silicon-based cell-engineering platform to create a novel delivery approach. Their approach, Iris, is a System-on-a-Chip delivery platform that enables targeted delivery, multiplexing and dose control with digital precision. Iris delivers nucleic acids, protein complexes and small molecules into cells, enabling Mekonos to partner with many companies and teams to test and further develop their cell and gene therapy products. For example, Mekonos has partnered with Neochromosome to advance cell engineering for personalized medicines.</p>


Mekonos

Founded: 2017
Location: San Francisco, CA
Employee range: 11 - 50
Funding: $25M Nov 2021; $4.6M Nov 2020

Short description:

Drug notes:

Long description:

Jobs: